{"id":"spd503-guanfacine-hcl","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Somnolence"},{"rate":"15-20","effect":"Fatigue"},{"rate":"10-15","effect":"Headache"},{"rate":"8-12","effect":"Dizziness"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5-8","effect":"Bradycardia"},{"rate":"5-10","effect":"Dry mouth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Guanfacine selectively binds to alpha-2A adrenergic receptors in the brain, particularly in the prefrontal cortex, which decreases norepinephrine signaling and enhances working memory and executive function. This mechanism helps reduce symptoms of inattention and hyperactivity-impulsivity. SPD503 is an extended-release formulation designed to provide sustained therapeutic levels throughout the day.","oneSentence":"Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine activity in the prefrontal cortex to improve attention and impulse control.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:44.542Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"}]},"trialDetails":[{"nctId":"NCT04085172","phase":"PHASE4","title":"A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2019-09-18","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":396},{"nctId":"NCT01500694","phase":"PHASE3","title":"Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe","status":"COMPLETED","sponsor":"Shire","startDate":"2012-03-20","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":215},{"nctId":"NCT00901576","phase":"PHASE1","title":"A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2009-05-18","conditions":"Healthy","enrollment":38},{"nctId":"NCT00734578","phase":"PHASE3","title":"Efficacy and Safety of SPD503 in Combination With Psychostimulants","status":"COMPLETED","sponsor":"Shire","startDate":"2008-09-02","conditions":"ADHD","enrollment":461},{"nctId":"NCT00919867","phase":"PHASE1","title":"A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2009-06-24","conditions":"Healthy","enrollment":42},{"nctId":"NCT00367835","phase":"PHASE3","title":"SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms","status":"COMPLETED","sponsor":"Shire","startDate":"2006-12-04","conditions":"ADHD","enrollment":217},{"nctId":"NCT00151996","phase":"PHASE2","title":"Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2004-08-16","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":75},{"nctId":"NCT00152009","phase":"PHASE3","title":"Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2003-01-29","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":345},{"nctId":"NCT01470469","phase":"PHASE2","title":"SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)","status":"COMPLETED","sponsor":"Shire","startDate":"2012-01-04","conditions":"Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social","enrollment":83},{"nctId":"NCT00150618","phase":"PHASE3","title":"Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2004-03-30","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":324},{"nctId":"NCT00150592","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2005-05-12","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":182},{"nctId":"NCT00997984","phase":"PHASE3","title":"Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)","status":"COMPLETED","sponsor":"Shire","startDate":"2009-11-17","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":340},{"nctId":"NCT03662763","phase":"PHASE3","title":"Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2011-09","conditions":"Attention Deficit Disorder","enrollment":12},{"nctId":"NCT01156051","phase":"PHASE4","title":"Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia","status":"TERMINATED","sponsor":"Children's Specialized Hospital","startDate":"2010-06","conditions":"Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intuniv"],"phase":"phase_3","status":"active","brandName":"SPD503 (Guanfacine HCl)","genericName":"SPD503 (Guanfacine HCl)","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine activity in the prefrontal cortex to improve attention and impulse control. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}